Connect with us

Health & Fitness

‘Poster Child for Limited Evidence of Benefit’: What We Heard This Week

(MedPage Today) — “Gabapentin is sort of the poster child for limited evidence of benefit.” — Donovan Maust, MD, MS, of the University of Michigan in Ann Arbor, on a study of polypharmacy in patients with dementia. “There’s no unseeing and…

Published

on

‘Poster Child for Limited Evidence of Benefit’: What We Heard This Week